On Wednesday, the company issued a statement, attributed to Soriot, saying AstraZeneca would be guided by a committee of independent experts in determining when to lift the hold on the trial "so that we can continue our work at the earliest opportunity to provide this vaccine broadly, equitably and at no profit during this pandemic".
Developers globally have yet to produce large-scale trial data showing actual infections in participants, yet Russian Federation granted approval to a COVID-19 vaccine last month, prompting some Western experts to criticise a lack of testing. A "standard review process has been triggered, leading to the voluntary pause of vaccination across all trials", according to a statement from the company on Wednesday.
The vaccine is being developed by Oxford University and AstraZeneca, and the illness of the volunteer has yet to be disclosed publicly.
One such vaccine is being developed by AstraZeneca, which has had to pause global trials after an unexplained illness in a participant in Britain. Those tests will be delivered to an independent safety committee that will review the event and establish a final diagnosis.
"We are optimistic that among these candidates there will be a safe and effective vaccine against Covid-19 to help us defeat this pandemic", European Union health commissioner Stella Kyriakides said without elaborating on a possible date contrary to her recent statements that the European Union expected a vaccine by the end of the year.More news: Newcastle bring in Northern Ireland full-back Lewis for a reported €16.5m
There are now dozens of vaccines in varying stages of clinical trials around the world.
According to a Phase 1/2 study published in July, about 60 percent of 1,000 participants given the vaccine experienced mild to moderate side effects such as headaches, muscle pain or fever.
One Phase 3 trial has been underway in the United States since late August with plans to enroll up to 30,000 participants at 80 sites across the country. All of them are still listed by the World Health Organization as being in clinical trials.More news: Donald Trump asks 'muffled' reporter to remove face mask
Governor João Dória added that Phase 2 trials of the potential vaccine had shown an immune response of 98% in the elderly.
The participant - a woman in the United Kingdom - showed neurological symptoms often associated with transverse myelitis, a condition where the spinal cord becomes inflamed, AstraZeneca CEO Pascal Soriot told investors during a private call on Sep. "I could not possibly tell you right now because I don't know what's going to happen in the coming months", he said.
A few potential vaccines are now undergoing clinical evaluation. Such events are routine in major trials, and happen any time a volunteer is admitted to hospital when the cause of their illness is not immediately apparent.
Earlier this summer, the AstraZeneca/Oxford trial was paused when a patient developed neurological symptoms.
European Union officials also recently suggested that they were hoping to have market authorisation of the vaccine as early as November, depending on the success of AstraZeneca's vaccine phase III clinical trial.More news: Lily Allen & David Harbour ARE Married! See The AMAZING Vegas Wedding Pics!
It is unclear how long the pause on Phase 3 might last. The other two companies, Moderna and BioNTech, are developing vaccines using different methods than those used by AstraZeneca.